Trial start —: The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach t source ↗
Raise IPO: $314M (total, as published), announced Nov 7, 2025. Source: company release on GlobeNewswire. source ↗
Upcoming milestones
2027-12 (ESTIMATED) · · The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to N · NCT07643896
Estimated primary completion per ClinicalTrials.gov. Dates move.
Funding
Raised: $314.0M. Last 2 years.
IPO: $314M (total, as published), announced Nov 7, 2025. Source: company release on GlobeNewswire. source ↗
The ADVANCE (Assay Development and Validation for Pre-Natal and Obstetric Conditions) Study is the Largest U.S.-Based Prospective Study Demonstrating a Circulating Fetal Cell (CFC) Based Approach to Non-invasive Fetal Risk Assessment
Not listed
Recruiting
Jan 10, 2026
2027-12 (estimated)
Open jobs 85
2 patient-care jobs hidden (phlebotomy, plasma-center, nursing and similar care roles; 87 open jobs in total).
Level (Entry/Mid/Senior/Executive) is estimated from the job title and required years of experience. Descriptions are short excerpts (about the first 60 words) of the posting plus skills picked out of it; use Read full posting for the complete text.